<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002684</url>
  </required_header>
  <id_info>
    <org_study_id>95-031</org_study_id>
    <secondary_id>CDR0000064373</secondary_id>
    <secondary_id>NCI-V95-0743</secondary_id>
    <nct_id>NCT00002684</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer</brief_title>
  <official_title>Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, use
      different ways to stop tumor cells from dividing so they stop growing or die. Combining more
      than one drug and giving drugs in different ways may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating
      patients with metastatic urinary tract cancer that cannot be treated with surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with
           unresectable or metastatic urothelial cancer (nontransitional cell histologies).

      OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1
      and ifosfamide IV over 1 hour on days 1-3. Filgrastim (G-CSF) is administered subcutaneously
      daily beginning on day 6 and continuing through day 17 or until blood counts recover.
      Treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or
      progressive disease after completion of course 2 or complete response after completion of
      course 4.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urethral Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven unresectable or metastatic urothelial cancer

               -  No transitional cell histologies

          -  Bidimensionally measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Hematopoietic:

          -  WBC at least 3,500/mm^3

          -  Platelet count greater than 150,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL

        Renal:

          -  Creatinine less than 1.5 mg/dL OR

          -  Creatinine clearance greater than 55 mL/min

        Cardiovascular:

          -  No New York Heart Association class III or IV heart disease

        Other:

          -  No other concurrent malignancy except basal cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior systemic chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 3 weeks since prior radiotherapy

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean F. Bajorin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 2, 2013</last_update_submitted>
  <last_update_submitted_qc>July 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <keyword>stage III bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>squamous cell carcinoma of the bladder</keyword>
  <keyword>adenocarcinoma of the bladder</keyword>
  <keyword>recurrent urethral cancer</keyword>
  <keyword>distal urethral cancer</keyword>
  <keyword>proximal urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

